Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 7/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10279053 | 0.87 | F2R (0.47) | F2RCNR1TMEM97EPHX2 | |
| SCHEMBL641260 | 0.81 | F2R (0.67) | F2RCNR1TMEM97HSD11B1KDM2B | |
| SCHEMBL641261 | 0.80 | F2R (0.69) | F2RCNR1TMEM97HSD11B1KDM2B | |
| SCHEMBL640933 | 0.80 | F2R (0.65) | F2RCNR1TMEM97HSD11B1KDM2B | |
| SCHEMBL642493 | 0.79 | F2R (0.57) | F2RCNR1TMEM97FAAHEPHX2 | |
| SCHEMBL12720268 | 0.78 | F2R (0.64) | F2RCNR1TMEM97HSD11B1KDM2B | |
| SCHEMBL641795 | 0.78 | F2R (0.63) | F2RCNR1TMEM97HSD11B1KDM2B | |
| SCHEMBL642635 | 0.78 | F2R (0.61) | F2RCNR1TMEM97FAAHMGLL | |
| SCHEMBL641974 | 0.77 | F2R (0.62) | F2RCNR1TMEM97HSD11B1FAAH | |
| SCHEMBL12720197 | 0.76 | F2R (0.59) | F2RCNR1TMEM97FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | F2R 698/4885CNR1 454/4885TMEM97 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.